BeiGene, Ltd. (NASDAQ:BGNE) Insider Sells $7,692,966.80 in Stock

BeiGene, Ltd. (NASDAQ:BGNE) insider Xiaodong Wang sold 40,468 shares of the stock in a transaction dated Tuesday, November 26th. The stock was sold at an average price of $190.10, for a total transaction of $7,692,966.80. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website.

BeiGene Trading Up 4.3 %

Shares of BGNE stock traded up $8.84 during mid-day trading on Friday, reaching $215.00. The company’s stock had a trading volume of 258,572 shares, compared to its average volume of 266,091. The firm has a market capitalization of $20.94 billion, a PE ratio of -26.09 and a beta of 0.63. The company has a quick ratio of 1.72, a current ratio of 1.93 and a debt-to-equity ratio of 0.05. BeiGene, Ltd. has a 12-month low of $126.97 and a 12-month high of $248.16. The company’s 50 day simple moving average is $212.42 and its 200-day simple moving average is $184.46.

BeiGene (NASDAQ:BGNE) last released its earnings results on Tuesday, November 12th. The company reported ($1.15) earnings per share for the quarter, missing the consensus estimate of ($1.11) by ($0.04). The firm had revenue of $1 billion during the quarter, compared to analysts’ expectations of $983.26 million. BeiGene had a negative return on equity of 25.12% and a negative net margin of 25.94%. The business’s revenue was up 28.2% on a year-over-year basis. During the same period last year, the business earned $2.01 earnings per share. On average, research analysts predict that BeiGene, Ltd. will post -5.38 EPS for the current fiscal year.

Analysts Set New Price Targets

BGNE has been the topic of several research analyst reports. Citigroup upped their price objective on BeiGene from $269.00 to $288.00 and gave the company a “buy” rating in a research report on Thursday, August 8th. StockNews.com downgraded BeiGene from a “buy” rating to a “hold” rating in a research report on Thursday, November 21st. JPMorgan Chase & Co. lifted their target price on BeiGene from $200.00 to $235.00 and gave the company an “overweight” rating in a research report on Tuesday, October 22nd. JMP Securities began coverage on BeiGene in a research note on Wednesday, September 18th. They issued a “market outperform” rating and a $288.00 price objective for the company. Finally, TD Cowen boosted their target price on BeiGene from $254.00 to $260.00 and gave the company a “buy” rating in a report on Wednesday, November 13th. Three analysts have rated the stock with a hold rating and five have issued a buy rating to the company. According to data from MarketBeat.com, the company presently has an average rating of “Moderate Buy” and a consensus target price of $247.07.

Hedge Funds Weigh In On BeiGene

Hedge funds have recently made changes to their positions in the business. Blue Trust Inc. raised its holdings in BeiGene by 156.3% during the 3rd quarter. Blue Trust Inc. now owns 123 shares of the company’s stock worth $28,000 after buying an additional 75 shares during the period. Allspring Global Investments Holdings LLC bought a new stake in shares of BeiGene during the third quarter worth about $36,000. Point72 Asia Singapore Pte. Ltd. bought a new stake in BeiGene in the third quarter valued at approximately $67,000. SG Americas Securities LLC acquired a new position in BeiGene in the third quarter valued at approximately $105,000. Finally, PFG Investments LLC bought a new stake in shares of BeiGene in the 3rd quarter worth $210,000. Institutional investors and hedge funds own 48.55% of the company’s stock.

About BeiGene

BeiGene, Ltd., through its subsidiaries, engages in the development and commercialization of oncology medicines worldwide. Its products include BRUKINSA to treat various blood cancers; TEVIMBRA to treat various solid tumor and blood cancers; PARTRUVIX for the treatment of various solid tumor malignancies; XGEVA to treat bone metastases from solid tumors and multiple myeloma, as well as giant cell tumor of bone; BLINCYTO to treat acute lymphoblastic leukemia; KYPROLIS to treat R/R multiple myeloma; REVLIMID to treat multiple myeloma; VIDAZA to treat myelodysplastic syndromes, chronic myelomonocyte leukemia, and acute myeloid leukemia; SYLVANT to treat idiopathic multicentric castleman disease; QARZIBA to treat neuroblastoma; POBEVCY to treat metastatic colorectal cancer, liver cancer, and non-small cell lung cancer (NSCLC); BAITUOWEI, to treat breast and prostate cancers; TAFINLAR and MEKINIST to treat NSCLC and melanoma; VOTRIENT for advance renal cell carcinoma; AFINITOR for advance renal cell carcinoma, NET, SEGA, & breast cancers; and ZYKADIA to treat ALK + NSCLC.